vs
Side-by-side financial comparison of Loar Holdings Inc. (LOAR) and Vericel Corp (VCEL). Click either name above to swap in a different company.
Loar Holdings Inc. is the larger business by last-quarter revenue ($131.8M vs $92.9M, roughly 1.4× Vericel Corp). Vericel Corp runs the higher net margin — 25.0% vs 9.5%, a 15.5% gap on every dollar of revenue. On growth, Vericel Corp posted the faster year-over-year revenue change (23.3% vs 19.3%). Over the past eight quarters, Vericel Corp's revenue compounded faster (34.6% CAGR vs 19.8%).
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.
LOAR vs VCEL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $131.8M | $92.9M |
| Net Profit | $12.5M | $23.2M |
| Gross Margin | 52.1% | 78.7% |
| Operating Margin | 18.0% | 24.1% |
| Net Margin | 9.5% | 25.0% |
| Revenue YoY | 19.3% | 23.3% |
| Net Profit YoY | 239.5% | 17.3% |
| EPS (diluted) | $0.13 | $0.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $131.8M | $92.9M | ||
| Q3 25 | $126.8M | $67.5M | ||
| Q2 25 | $123.1M | $63.2M | ||
| Q1 25 | $114.7M | $52.6M | ||
| Q4 24 | $110.4M | $75.4M | ||
| Q3 24 | $103.5M | $57.9M | ||
| Q2 24 | $97.0M | $52.7M | ||
| Q1 24 | $91.8M | $51.3M |
| Q4 25 | $12.5M | $23.2M | ||
| Q3 25 | $27.6M | $5.1M | ||
| Q2 25 | $16.7M | $-553.0K | ||
| Q1 25 | $15.3M | $-11.2M | ||
| Q4 24 | $3.7M | $19.8M | ||
| Q3 24 | $8.7M | $-901.0K | ||
| Q2 24 | $7.6M | $-4.7M | ||
| Q1 24 | $2.2M | $-3.9M |
| Q4 25 | 52.1% | 78.7% | ||
| Q3 25 | 52.7% | 73.5% | ||
| Q2 25 | 53.8% | 73.7% | ||
| Q1 25 | 52.1% | 69.0% | ||
| Q4 24 | 48.9% | 77.6% | ||
| Q3 24 | 51.1% | 71.9% | ||
| Q2 24 | 49.0% | 69.5% | ||
| Q1 24 | 48.4% | 68.9% |
| Q4 25 | 18.0% | 24.1% | ||
| Q3 25 | 22.9% | 5.1% | ||
| Q2 25 | 22.2% | -3.2% | ||
| Q1 25 | 22.8% | -24.3% | ||
| Q4 24 | 19.2% | 24.5% | ||
| Q3 24 | 22.1% | -4.3% | ||
| Q2 24 | 22.9% | -11.5% | ||
| Q1 24 | 23.3% | -10.7% |
| Q4 25 | 9.5% | 25.0% | ||
| Q3 25 | 21.8% | 7.5% | ||
| Q2 25 | 13.6% | -0.9% | ||
| Q1 25 | 13.4% | -21.4% | ||
| Q4 24 | 3.3% | 26.3% | ||
| Q3 24 | 8.4% | -1.6% | ||
| Q2 24 | 7.9% | -8.9% | ||
| Q1 24 | 2.4% | -7.5% |
| Q4 25 | $0.13 | $0.46 | ||
| Q3 25 | $0.29 | $0.10 | ||
| Q2 25 | $0.17 | $-0.01 | ||
| Q1 25 | $0.16 | $-0.23 | ||
| Q4 24 | $-11023.48 | $0.40 | ||
| Q3 24 | $0.09 | $-0.02 | ||
| Q2 24 | $0.09 | $-0.10 | ||
| Q1 24 | $11023.54 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $84.8M | $137.5M |
| Total DebtLower is stronger | $715.7M | — |
| Stockholders' EquityBook value | $1.2B | $354.6M |
| Total Assets | $2.0B | $488.0M |
| Debt / EquityLower = less leverage | 0.61× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $84.8M | $137.5M | ||
| Q3 25 | $99.0M | $135.4M | ||
| Q2 25 | $103.3M | $116.9M | ||
| Q1 25 | $80.5M | $112.9M | ||
| Q4 24 | $54.1M | $116.2M | ||
| Q3 24 | $55.2M | $101.7M | ||
| Q2 24 | $73.2M | $102.5M | ||
| Q1 24 | $28.2M | $110.6M |
| Q4 25 | $715.7M | — | ||
| Q3 25 | $279.4M | — | ||
| Q2 25 | $277.7M | — | ||
| Q1 25 | $277.5M | — | ||
| Q4 24 | $277.3M | — | ||
| Q3 24 | $602.1M | — | ||
| Q2 24 | $250.7M | — | ||
| Q1 24 | $534.2M | — |
| Q4 25 | $1.2B | $354.6M | ||
| Q3 25 | $1.2B | $321.9M | ||
| Q2 25 | $1.1B | $306.8M | ||
| Q1 25 | $1.1B | $295.5M | ||
| Q4 24 | $1.1B | $292.0M | ||
| Q3 24 | $769.8M | $257.5M | ||
| Q2 24 | $758.4M | $243.0M | ||
| Q1 24 | $420.6M | $233.9M |
| Q4 25 | $2.0B | $488.0M | ||
| Q3 25 | $1.5B | $453.3M | ||
| Q2 25 | $1.5B | $435.6M | ||
| Q1 25 | $1.5B | $424.6M | ||
| Q4 24 | $1.5B | $432.7M | ||
| Q3 24 | $1.5B | $390.4M | ||
| Q2 24 | $1.1B | $376.8M | ||
| Q1 24 | $1.1B | $356.7M |
| Q4 25 | 0.61× | — | ||
| Q3 25 | 0.24× | — | ||
| Q2 25 | 0.25× | — | ||
| Q1 25 | 0.25× | — | ||
| Q4 24 | 0.25× | — | ||
| Q3 24 | 0.78× | — | ||
| Q2 24 | 0.33× | — | ||
| Q1 24 | 1.27× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $15.0M |
| Free Cash FlowOCF − Capex | — | $12.8M |
| FCF MarginFCF / Revenue | — | 13.8% |
| Capex IntensityCapex / Revenue | — | 2.4% |
| Cash ConversionOCF / Net Profit | 2.43× | 0.65× |
| TTM Free Cash FlowTrailing 4 quarters | — | $24.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $15.0M | ||
| Q3 25 | $29.7M | $22.1M | ||
| Q2 25 | $23.8M | $8.2M | ||
| Q1 25 | $28.4M | $6.6M | ||
| Q4 24 | $20.7M | $22.2M | ||
| Q3 24 | $16.3M | $10.2M | ||
| Q2 24 | $7.1M | $18.5M | ||
| Q1 24 | $10.8M | $7.2M |
| Q4 25 | — | $12.8M | ||
| Q3 25 | — | $19.5M | ||
| Q2 25 | — | $81.0K | ||
| Q1 25 | — | $-7.6M | ||
| Q4 24 | — | $8.5M | ||
| Q3 24 | — | $-9.2M | ||
| Q2 24 | — | $1.8M | ||
| Q1 24 | — | $-6.8M |
| Q4 25 | — | 13.8% | ||
| Q3 25 | — | 28.8% | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | — | -14.5% | ||
| Q4 24 | — | 11.2% | ||
| Q3 24 | — | -15.9% | ||
| Q2 24 | — | 3.4% | ||
| Q1 24 | — | -13.3% |
| Q4 25 | — | 2.4% | ||
| Q3 25 | — | 3.9% | ||
| Q2 25 | — | 12.9% | ||
| Q1 25 | — | 27.0% | ||
| Q4 24 | — | 18.3% | ||
| Q3 24 | — | 33.5% | ||
| Q2 24 | — | 31.8% | ||
| Q1 24 | — | 27.3% |
| Q4 25 | 2.43× | 0.65× | ||
| Q3 25 | 1.08× | 4.35× | ||
| Q2 25 | 1.42× | — | ||
| Q1 25 | 1.85× | — | ||
| Q4 24 | 5.62× | 1.12× | ||
| Q3 24 | 1.89× | — | ||
| Q2 24 | 0.93× | — | ||
| Q1 24 | 4.81× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LOAR
| Other | $76.8M | 58% |
| Commercial Aerospace | $21.2M | 16% |
| Business Jet And General Aviation | $17.6M | 13% |
| Defense | $16.2M | 12% |
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
